Airdoc 鷹瞳

Beijing Airdoc Technology Co., Ltd.

北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2251)

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE 2024 H SHARE FULL CIRCULATION

INTRODUCTION

References are made to the announcements of Beijing Airdoc Technology Co., Ltd. (the "**Company**") dated August 28, 2024 and April 28, 2025, and the circular of the Company dated September 27, 2024 in relation to, among others, the Company's application for, and receiving official approval from CSRC, the 2024 H Share Full Circulation. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the aforesaid announcements and circular.

LISTING APPROVAL

The Company is pleased to announce that it recently received from the Stock Exchange the approval (subject to fulfillment of all other conditions of the Conversion and Listing) for the listing of and permission to deal in 50,151,012 H Shares (the "**Converted H Shares**"), representing the maximum number of the Unlisted Shares to be converted into H Shares pursuant to the Conversion and Listing under the 2024 H Share Full Circulation.

SHAREHOLDING STRUCTURE

The Conversion and Listing will involve an aggregate of 50,151,012 Unlisted Shares held by a total of 26 participating holders (the "**Participating Shareholders**"). The following table sets out the number of Converted H Shares held by each Participating Shareholder and the corresponding percentage as to the total issued Shares of the Company upon completion of the Conversion and Listing.

No.	Name of Participating Shareholder	Number of Converted H Shares[(1)]	Approximate percentage of the total issued Shares upon completion of the Conversion and Listing[(2)]
1.	ZHANG Dalei	12,074,198	11.66%
2.	Beijing Airdoc Universe Technology Center L.P.	2,335,363	2.25%
3.	CHEN Mingqiang	956,380	0.92%
4.	GAO Fei	441,678	0.43%
5.	Shanghai Huliu Investment Management Co. Ltd.	7,169,737	6.92%
6.	Suqian Airdoc Technology Center (Limited Partnership)	3,756,431	3.63%
7.	Yadong Beichen Venture Investment Co., Ltd.	3,424,168	3.31%
8.	Suqian Zhongyou Technology Center (Limited Partnership)	2,319,588	2.24%
9.	Jinan Chanyan Zhongxiang Equity Investment Management Center (Limited Partnership)	2,314,816	2.24%
10.	Shenzhen Kaiyan Mingzhi Investment Fund (Limited Partnership)	2,311,521	2.23%
11.	Suzhou Zhilang Guangcheng Venture Center (Limited Partnership)	2,201,988	2.13%
12.	Beijing Jiuhe Yunteng Investment Center (Limited Partnership)	1,454,144	1.40%
13.	Ruizhixin (Shenzhen) Technology Industry Development Co., Ltd.	1,442,606	1.39%
14.	CITIC (Shenzhen) Venture Capital Equity Investment Fund Partnership (Limited Partnership)	1,442,606	1.39%

No.	Name of Participating Shareholder	Number of Converted H Shares(1)	Approximate percentage of the total issued Shares upon completion of the Conversion and Listing(2)
15.	Niyajiala (Tianjin) Investment Co. Ltd.	1,157,408	1.12%
16.	Guoke Kaiyan I (Shenzhen) Intelligent Medical Investment Fund (Limited Partnership)	751,744	0.73%
17.	Beijing Fuhoinnovation Venture Investment Management Center (Limited Partnership)	763,014	0.74%
18.	Shanghai Morong Investment Center (Limited Partnership)	696,925	0.67%
19.	Shanghai Nengjun Chuangye Venture Investment Center (Limited Partnership)	516,243	0.50%
20.	China Everbright Healthcare Co., Ltd.	462,961	0.45%
21.	Tianjin Xishan Partner Technology Partnership (Limited Partnership)	468,874	0.45%
22.	Nanjing Fanghua Equity Investment Fund (Limited Partnership)	462,963	0.45%
23.	Aranya Holding Group Co., Limited	462,961	0.45%
24.	Suzhou Zhilang Fengcheng Venture Investment Center (Limited Partnership)	415,471	0.40%
25.	Sansheng Guojian Pharmaceutical (Shanghai) Co., Ltd.	231,481	0.22%
26.	Wenzhou Haiyin Qianshao Equity Investment Fund (Limited Partnership)	115,743	0.11%
	Total	**50,151,012**	**48.42%**

Notes:

(1) Representing only the H Shares converted from the Unlisted Shares held by relevant Shareholders prior to completion of the Conversion and Listing under the 2024 H Share Full Circulation. For the avoidance of doubt, certain Shareholders held H Shares prior to the Conversion and Listing.

(2) Assuming no other changes are made to the shareholding structure of the Company and the number of Shares held by the Participating Shareholders remains unchanged.

The share capital structure of the Company as of the date of this announcement and upon completion of the Conversion and Listing (assuming all of the 50,151,012 Unlisted Shares are converted into H Shares and no other changes are made to the issued share capital of the Company) is set out below:

Type of Shares	As of the date of this announcement		Upon completion of the Conversion and Listing	
	Number of Shares	*Approximate percentage*	*Number of Shares*	*Approximate percentage*
H Shares	53,417,001[(1)]	51.58%	103,568,013[(1)]	100%
Unlisted Shares	50,151,012	48.42%	—	0%
Total	**103,568,013**	**100.00%**	**103,568,013**	**100.00%**

Note:

(1) Including 412,000 H Shares held by the Company as treasury Shares.

CONVERSION AND TRADING PROCEDURES

With their authorization and on behalf of the Participating Shareholders, the Company will complete the cancellation registration procedure for the Unlisted Shares held by the Participating Shareholders in China Securities Depository and Clearing Corporation Limited (the "**China Clearing**") Shenzhen Branch.

The Company will complete the following procedures in connection with the Conversion and Listing:

(i) for holders of the Unlisted Shares who are People's Republic of China (the "**PRC**") nationals, with their authorization and on behalf of the Participating Shareholders, the Company will appoint China Clearing as the nominee to deposit the relevant securities of the PRC nationals (the "**Relevant Securities**") at China Securities Depository and Clearing (Hong Kong) Company Limited ("**China Clearing HK**") and China Clearing HK in its own name will deposit the Relevant Securities at Hong Kong Securities Clearing Company Limited ("**HKSCC**"). China Clearing as the nominee of the Participating Shareholders, who are PRC nationals, will handle all custody, maintenance of detailed records, cross-border settlement and corporate actions etc. relating to the Converted H Shares for the Participating Shareholders who are PRC nationals;

(ii) the Company will instruct the H Share registrar of the Company, Tricor Investor Services Limited, in relation to the issue of the relevant share certificates of the Converted H Shares; and

(iii) the Company will make arrangements to enable the Converted H Shares to be accepted as eligible securities by HKSCC for deposit, clearance and settlement in the Central Clearing and Settlement System.

The holders of the Converted H Shares who are PRC nationals can only conduct share trading after the below arrangement procedures relating to the registration, depositary and transaction settlement of the Conversion and Listing are completed:

(i) the Company will apply to China Clearing, Shenzhen Branch for the maintenance of the detailed records of the initial holding of the Converted H Shares held by the relevant holders. Meanwhile, the Company will submit applications for a domestic transaction commission code and abbreviation, which will be confirmed by China Clearing, Shenzhen Branch pursuant to the authorization of the Shenzhen Stock Exchange (the "**Shenzhen Stock Exchange**");

(ii) the Shenzhen Stock Exchange authorizes Shenzhen Securities Communication Co., Ltd. to provide services relating to trading entrustment orders and transmission of trading messages between a domestic securities company (the "**Domestic Securities Company**") and a Hong Kong securities company (the "**Hong Kong Securities Company**") for the Converted H Shares, and the real-time market forwarding services of the relevant H Shares;

(iii) according to the "Guidelines for Foreign Exchange Business under Capital Accounts (2024 Edition)" (《資本項目外匯業務指引(2024年版)》) issued by the State Administration of Foreign Exchange of the PRC, the holders of the Converted H Shares who are PRC nationals should complete the overseas shareholding registration with the local foreign exchange administration bureau within 20 business days prior to increasing their holdings, collect the registration certificate and then present such certificate to a domestic securities company to proceed with the shareholding increase; and

(iv) the holders of the Converted H Shares who are PRC nationals should, through the specified account, submit entrusted trading order of the Converted H Shares through the Domestic Securities Company. The relevant orders of the holders of the Converted H Shares will be submitted to the Stock Exchange for trading through the securities trading account opened by the Domestic Securities Company at the Hong Kong Securities Company. After completion of the transaction, the Hong Kong Securities Company and China Clearing HK, China Clearing HK and China Clearing, China Clearing and the Domestic Securities Company, the Domestic Securities Company and the holders of the Converted H Shares will conduct settlement respectively.

In addition, according to the "Guidelines for Foreign Exchange Business under Capital Accounts (2024 Edition)" (《資本項目外匯業務指引(2024年版)》), the holders of the Converted H Shares who are PRC nationals should complete the overseas shareholding registration with the local foreign exchange administration bureau within 20 business days after reducing their holdings, collect the registration certificate and then present such certificate to a domestic bank to proceed with the opening of relevant accounts.

Further announcement(s) in connection with the subject matter will be made by the Company when and where appropriate.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, May 26, 2025

As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Ms. WANG Lin, Dr. HE Chao and Mr. QIN Yong as executive Directors; and Dr. WU Yangfeng, Dr. HUANG Yanlin and Mr. NG Ho Yin Owen as independent non-executive Directors.